Bauer Marta, Glowacka Magdalena, Kamysz Wojciech, Kleczkowska Patrycja
Department of Analytical Chemistry, Faculty of Pharmacy, Medical University of Gdansk, 80-416 Gdansk, Poland.
Institute of Psychology and Human Sciences, WSEI Academy, 20-209 Lublin, Poland.
Int J Mol Sci. 2024 Nov 23;25(23):12601. doi: 10.3390/ijms252312601.
Marine-derived peptides display potent antihypertensive, antioxidant, analgesic and antimicrobial biological effects. Some of them have also been found to have anticancer activity via various mechanisms differing from those of continental organisms. This diversity of properties-together with the peptides' efficacy, which has been confirmed in several in vitro and in vivo studies-make these compounds attractive as functional ingredients in pharmacy, especially in regard to multitarget drugs known as hybrids. Given the possibilities offered by chimeric structures, it is expected that a hybridization strategy based on a marine-derived compound could result in a long-awaited success in the development of new effective compounds to combat a range of complex diseases. However, despite the fact that the biological activity of such new hybrids may exceed that of their parent compounds, there is still an urgent need to carefully determine their potential off-targets and thus possible clinically important side effects. Given the above, the aim of this paper is to provide information on compounds of marine origin with peptide structures and to verify the occurrence and usage of hybrid compounds built from these structures. Furthermore, the authors believe that information presented here will serve to increase public awareness of the new opportunities arising from the combination of hybridization strategies with marine molecules with known structures and biological properties, thereby accelerating the development of effective drug candidates.
海洋来源的肽具有强大的降压、抗氧化、镇痛和抗菌生物活性。其中一些还被发现通过与陆地生物不同的各种机制具有抗癌活性。这些多样的特性，以及肽的功效（已在多项体外和体内研究中得到证实），使得这些化合物作为药物中的功能成分具有吸引力，特别是对于称为杂合物的多靶点药物而言。鉴于嵌合结构所提供的可能性，预计基于海洋来源化合物的杂交策略可能会在开发对抗一系列复杂疾病的新有效化合物方面取得期待已久的成功。然而，尽管这种新杂合物的生物活性可能超过其母体化合物，但仍迫切需要仔细确定其潜在的脱靶效应以及由此可能产生的具有临床重要性的副作用。鉴于上述情况，本文的目的是提供有关具有肽结构的海洋来源化合物的信息，并验证由这些结构构建的杂合化合物的出现和用途。此外，作者认为本文提供的信息将有助于提高公众对杂交策略与具有已知结构和生物学特性的海洋分子相结合所带来的新机遇的认识，从而加速有效候选药物的开发。
